(redirected from Darunavir)
Also found in: Dictionary, Medical, Wikipedia.
Related to Darunavir: Raltegravir
DRVDeutscher Raiffeisen Verband
DRVData Recovery Vehicle
DRVInstrument Driver Application Programming Interface
DRVData Retention Voltage
DRVDirection des Ressources Vivantes (French: Direction of Living Resources, fisheries)
DRVDemocratic Republic of Vietnam
DRVDevice Driver (file name extension)
DRVDaily Reference Value
DRVDouble Regulating Valve
DRVDarunavir (pharmaceutical drug-HIV treatment)
DRVDiyala River Valley (Iraq)
References in periodicals archive ?
The primary objective of the study was to evaluate the efficacy of darunavir in connection with the different patterns of virus resistance, when darunavir is used in combination with low-dose ritonavir and other ARV medications in subtype F HIV-1 infected, treatment-experienced subjects in naturalistic settings.
Janssen-Cilag, a subsidiary of the Johnson & Johnson pharmaceutical company, has a marketing authorisation application for the approval of a once-daily fixed-dose antiretroviral combination tablet of HIV-1 medicine, darunavir with cobicistat, to the European Medicines Agency (EMA).
Darunavir, a protease inhibitor, was developed by Janssen, while cobicistat, a pharmacokinetic enhancer or boosting agent, was developed by Gilead Sciences Inc (Gilead).
Darunavir levels 1 month post initiation of treatment were within therapeutic range and viral load was <400 copies/ml.
New PIs such as darunavir (32) and tipranavir (33) have revolutionised the management of highly resistant patients overseas.
Tipranavir and darunavir were not available at the time of enrolment to this protocol.
In June 2011, Gilead entered into an agreement with Janssen R&D Ireland for the development of a fixed-dose combination of cobicistat and the protease inhibitor darunavir.
Electronic auction: supply of drug darunavir coated tablets 800 mg as part of the implementation of decree of the government of the russian federation of december 28, 2016 no.
There are no published data on ME score of lopinavir/ritonavir (lpv/r) and darunavir.
The company added that Tybost is indicated as a boosting agent for the HIV protease inhibitors atazanavir 300 mg once daily and darunavir 800 mg once daily as part of antiretroviral combination therapy in adults with HIV-1 infection.
US FDA PREGNANCY CATEGORIES FOR CURRENTLY APPROVED ANTIRETROVIRALS Drug FDA category Abacavir C Didanosine B Emtricitabine B Lamivudine C Stavudine C Tenofovir B Zalcitabine C Zidovudine C Delavirdine C Efavi renz D Nevirapine C Amprenavir C Atazanavir B Darunavir B Fosamprenavir C Indinavir C Lopinavir + C ritonavir Nelfinavir B Ritonavir B Saquinavir B Tipranavir C Enfuvirtide B FDA categories defined as: A: Adequate and well-controlled studies of pregnant women fail to demonstrate a risk to the fetus during the first trimester of pregnancy (and no evidence exists of risk during later trimesters).
Darunavir (TMC114, DRV) and tipranavir (TPV) are important new ritonavir-boosted protease inhibitors, with efficacy in patients who have had prior treatment failure with this class and whose viruses exhibit extensive resistance-conferring mutations in the protease gene.